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ABSTRACT
Objective To determine the efficacy of a 23-valent
pneumococcal polysaccharide vaccine in people at high
risk of pneumococcal pneumonia.
Design Prospective, randomised, placebo controlled
double blind study.
Setting Nursing homes in Japan.
Participants 1006 nursing home residents.
Interventions Participants were randomly allocated to
either 23-valent pneumococcal polysaccharide vaccine
(n=502) or placebo (n=504).
MainoutcomemeasuresTheprimaryend pointswerethe
incidence of all cause pneumonia and pneumococcal
pneumonia. Secondary end points were deaths from
pneumococcal pneumonia, all cause pneumonia, and
other causes.
ResultsPneumoniaoccurredin63(12.5%)participantsin
the vaccine group and 104 (20.6%) in the placebo group.
Pneumococcal pneumonia was diagnosed in 14 (2.8%)
participants in the vaccine group and 37 (7.3%) in the
placebo group (P<0.001). All cause pneumonia and
pneumococcal pneumonia were significantly more
frequent in the placebo group than in the vaccine group:
incidence per 1000 person years 55 v 91 (P<0.0006) and
12v32(P<0.001),respectively.Deathfrompneumococcal
pneumonia was significantly higher in the placebo group
than in the vaccine group (35.1% (13/37) v 0% (0/14),
P<0.01).Thedeathratefromallcausepneumonia(vaccine
group 20.6% (13/63) v placebo group 25.0% (26/104),
P=0.5) and from other causes (vaccine group 17.7% (89/
502) v placebo group (80/504) 15.9%, P=0.4) did not
differ between the two study groups.
Conclusion The 23-valent pneumococcal polysaccharide
vaccine prevented pneumococcal pneumonia and
reduced mortality from pneumococcal pneumonia in
nursing home residents.
Trial registration Japan Medical Association Center for
Clinical Trials JMA-IIA00024.
INTRODUCTION
Although levels of pneumonia related morbidity and
mortality are high among residents of nursing homes,
with Streptococcus pneumoniae being the most common
pathogen,
1-3 the vaccination rate with the 23-valent
pneumococcal polysaccharide vaccine is low.
4 Out-
breaks of pneumococcal infection in nursing homes
have been reported when the vaccination rate is less
than5%.
5-7Onepossiblereasonforthelowvaccination
rateisthelackofclearevidenceshowingtheefficacyof
the23-valentpneumococcalpolysaccharidevaccinein
nursing home residents, despite the fact that it is gen-
erally recommended to those at high risk of pneumo-
coccal pneumonia.
8 Most evidence for the vaccine’s
efficacy is based on data from community acquired
pneumonia, in which large cohort trials, case-control
studies, and meta-analyses showed protection from
invasive pneumococcal disease.
9-14 However, no data
have been reported on the efficacy of the 23-valent
pneumococcal polysaccharide vaccine in nursing
home residents.
Althoughrandomisedcontrolledtrialsareapowerful
methodofshowingvaccineefficacy,anenormoussam-
plesizeisrequiredbecauseofthecurrentlowmorbidity
from pneumococcal pneumonia. For example, if a ran-
domised controlled trial were to be carried out for one
year among elderly (≥65) people in the United States
(incidence 2/1000/year), an estimated 22300 people
would need to be enrolled in each vaccine and placebo
group. If pneumococcal bacteraemia (0.53/1000/year)
weretheoutcometobemeasured,55600peoplewould
needtobeenrolledineachgroup.
15Onewaytoreduce
therequiredsamplesizewouldbetostudyapopulation
at high risk of pneumococcal pneumonia using more
sensitive diagnostic procedures than blood culture. An
appropriate diagnostic method for this purpose is the
urinary antigen test for Streptococcus pneumoniae, which
is non-invasive, not affected by use of antibiotics, and
has both high sensitivity and high specificity.
16 A study
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rural area of Japan (40.7/1000/year) showed an inci-
dence of pneumococcal pneumonia about 20 times
higher than in the elderly community dwelling popula-
tion (2/1000/year).
2
No national recommendation for vaccination
against pneumococcal pneumonia exists in Japan,
and thus only 3% of the older population (>65 years)
had been vaccinated in 2006, the year our trial began.
Avaccineprovedtobeeffectivewouldhaveanimpor-
tant impact on clinical outcome and the cost of health
care.Wecarriedoutaprospective,multicentre,double
blind, randomised and placebo controlled trial to
assess the efficacy of 23-valent pneumococcal poly-
saccharide vaccine on pneumococcal pneumonia and
all cause pneumonia in nursing home residents.
METHODS
Ninehospitalsand23hospitalaffiliatednursinghomes
collaborated in this study. We randomly assigned
participants to receive either 0.5 ml (25 μg in each)
23-valent pneumococcal polysaccharide vaccine
(Pneumovax, Merck, NJ) or 0.5 ml placebo (sodium
chloride) intramuscularly, in a double blind, multi-
centre study. Vaccine and placebo were presented in
identicalsingledosesyringeandneedlecombinations,
labelled with sequential study numbers only. A statis-
tician who was not on the study team carried out the
randomisation using a random number table, and
numbered the containers. A member of staff at Mie
University Hospital evaluated participants for eligibil-
ity to the study. Participants were assigned to their
group by blinded staff at the nursing homes. The
code was disclosed to the study investigators only at
the end of follow-up. Written informed consent was
obtainedfromtheparticipantsortheirnextofkin.Par-
ticipantswereincludedinthestudyfrom8March2006
to 25 January 2007, and the observation period ended
on 31 March 2009. All participants were therefore fol-
lowed-up for at least 26 months.
Study population
Nursing home residents were enrolled in the study
once eligibility had been ascertained. We excluded
people who were immunocompromised, because of a
presumed poor response to the vaccine (for example,
patients with myeloma, active malignant disease, a
neutrophil count <1.0×10
9/l, hypogammmaglobuli-
naemia, HIV infection, solid organ or bone marrow
transplantation, or those undergoing dialysis); people
of potentially low compliance, such as those unable to
follow study instructions; people who had ever
received a pneumococcal vaccine; and people with
hypersensitivity to the vaccine components.
Study design
Before entry into the study, the resident’s history was
taken,includingunderlyingdisease,aswellasinforma-
tion on smoking and alcohol consumption. A physical
examination was carried out and a blood sample
obtained before vaccination, after two months, and at
the end of the follow-up period. The medical staff who
tookcareoftheparticipantsreportedanysymptomsto
the study team investigators. To avoid missing any
casesofpneumonia,theinvestigatorinchargeensured
thattheparticipantsreceivedamedicalexaminationat
the nursing home once weekly. If pneumonia was sus-
pectedtheparticipantwasassessedattheaffiliatedhos-
pital; the medical staff at the nursing homes also
informed the study coordinator of the occurrence of
pneumonia or any other disease.
Pneumoniawasdiagnosedbythemedicalstaffofthe
respiratory unit at the affiliated hospital on the basis of
the presence of clinical symptoms and a new infiltrate
on chest radiography. Pneumococcal pneumonia was
diagnosed from a positive result in blood culture,
pleural fluid, or sputum (10
7 colony forming units per
millilitre in a purulent sample) or a positive pneumo-
coccalantigentestresultinurine.Duringthestudy,the
participants,theirfamily,orthe medicalstaffincharge
wereaskedtocontactthedoctorlocallyresponsiblefor
the study if the participant had any symptoms consis-
tent with a respiratory tract infection. If pneumonia
was clinically suspected then chest radiography was
carriedoutintheaffiliatedclinicorhospital.Theradio-
graph was evaluated by an independent reader, and in
mostcases(70%)chestcomputedtomographywascar-
riedoutfordiagnosticconfirmation.Ifpneumoniawas
confirmed, two samples of blood, sputum, and urine
were taken for microbiological examination. Only
Gram stained sputum samples displaying more than
25 leucocytes in a high power microscopic field and
fewer than 10 epithelial cells in a high power micro-
scopic field were used as diagnostic tools. The results
obtained with the pneumococcal antigen detection kit
(BinaxNOW S pneumoniae; Binax, NJ) were read at
15 minutes, as recommended by the manufacturer.
Cultures were quantified and expressed as colony
forming units per millilitre.
Assigned to placebo (n=504) Assigned to 23-valent
pneumococcal vaccine (n=502)
Completed trial (n=502)
1140 person years of observation
Completed trial (n=504)
1149 person years of observation
Consecutive eligible participants (n=1434)
Randomised (n=1006)
Alive at 31 March
(n=424, 84.1%)
Died (n=80, 15.9%) Alive at 31 March
(n=413, 82.3%)
Died (n=89, 17.7%)
Withdrawn (n=0)
Excluded (n=428):
  Did not consent (n=395)
  Other chronic disease (n=18)
  Missing cases (n=15)
Withdrawn (n=0)
Fig 1 | Flow diagram of trial
RESEARCH
page 2 of 7 BMJ | ONLINE FIRST | bmj.comAt all routine follow-up visits and in monthly discus-
sions with the participants or their family members as
well as the medical staff in charge, we ascertained
whethertheparticipantshadbeentreatedforpneumonia
or other diseases. If so, we requested the medical record
to ensure that we had not missed a case of pneumonia.
Ethics and conduct of the trial
A placebo controlled trial of vaccine efficacy has been
deemedunethicalin developednationswhere the vac-
cineisconsideredstandardofcare,evenintheabsence
of any proved efficacy. Pneumococcal vaccine is not
widely used in Japan because there is no national
recommendation for its use. The 23-valent pneumo-
coccal vaccine used in the current trial has a different
antigen content from other vaccines used in previous
randomised controlled trials.
1718
Because nursing home residents are cared for by
medicalstafftheyarebetterprotectedfromtheadverse
events of vaccination and easier to follow than older
people living in the community. In addition, vaccine
efficacy in a double blind, randomised and placebo
controlled trial was judged to be statistically evaluable
on the basis of previous findings.
2 If vaccine efficacy
was shown, the clinical and social implications would
beimportant.Thestudywasthereforeconsideredethi-
cally justified and approved by the Mie University
review board.
All participants fulfilled the criteria of safety
required for vaccine injection. No serious side effect
occurred after vaccination. At the end of the observa-
tion period (31 March 2009) the safety and efficacy
committee reviewed the unblinded data, found a sig-
nificantdifferenceintheprimaryendpointswithasuf-
ficient numberof events,and declaredthe termination
of the study.
Outcome measures and definitions
Theprimaryendpointswerepneumoniaandpneumo-
coccal pneumonia. The secondary end points were
deaths from pneumococcal pneumonia, all causes,
and other causes.
Exposuretimewasdefinedasthetimefromvaccina-
tiontotheendoffollow-up,oruntiltheoccurrenceofa
primary or secondary end point, or the allocation
sequence was disclosed during follow-up for reasons
other than a primary or secondary end point.
Statistical analysis
Sample size and power calculations were based on
reported morbidity from pneumococcal pneumonia
in nursing homes in rural Japan.
2 On the basis of the
results from this study, we set a follow-up period of up
tothreeyears.Thiswouldallowustoshowaprotective
effect of pneumococcal vaccine of about 50%, with a
powerof80%andastatisticalsignificanceof<5%,with
atotalnumberof700participants,43(12.21%)casesof
pneumococcalpneumonia,andaplacebogroupof350
participants.
Table 1 |Baseline characteristics of 1006 Japanese nursing home residents at randomisation
to 23-valent pneumococcal polysaccharide vaccine or placebo (sodium chloride). Values are
numbers (percentages) unless stated otherwise
Characteristics
Vaccine group
(n=502)
Placebo group
(n=504)
Mean (SD) age (years); range 84.7 (7.7); 55-102 84.8 (7.6); 56-105
Age group:
55-64 9 (1.8) 11 (2.2)
65-74 42 (8.4) 35 (6.9)
75-84 168 (33.5) 182 (36.1)
85-94 236 (47.0) 244 (48.4)
95-105 47 (9.4) 32 (6.3)
Men 111 (22.1) 109 (21.6)
Mean (SD) ECOG (performance status score*) 2.2 (0.9) 2.2 (0.9)
Mean (SD) body weight (kg) 43.8 (8.7) 43.8 (9.4)
Mean (SD) height (cm) 153.3 (6.8) 153.8 (7.1)
Mean (SD) body mass index 19.8 (3.7) 19.8 (3.6)
Vaccinated against influenza 500 (99.6) 500 (99.2)
Risk factors and comorbid conditions:
Smoker 31 (6.2) 29 (5.8)
Consumes alcohol† 25 (5.0) 21 (4.2)
Bedridden 58 (11.6) 50 (9.9)
Cerebrovascular disease 177 (35.3) 172 (34.1)
Chronic pulmonary disease‡ 36 (7.2) 34 (6.7)
Malignancy 11 (2.2) 8 (1.6)
Psychological disorder 29 (5.8) 20 (4.0)
Diabetes mellitus 50 (10.0) 54 (9.9)
Congestive heart failure 34 (6.8) 34 (6.7)
Other heart disease 43 (8.6) 44 (8.7)
Chronic liver disease 13 (2.6) 11 (2.2)
Chronic renal disease 10 (2.0) 15 (3.0)
Gastrostomy 7 (1.4) 8 (1.6)
Gastrectomy 1 (0.2) 4 (0.8)
Post-surgical 10 (2.0) 8 (1.6)
Bone fracture 3 (0.6) 4 (0.8)
Hypertension 101 (20.1) 114 (22.6)
Hyperlipidaemia 10 (2.0) 16 (3.2)
Other 29 (5.8) 40 (7.9)
No of comorbid conditions:
None 151 (30.1) 142 (28.2)
1 197 (39.2) 209 (41.5)
2 109 (21.7) 106 (21.0)
≥3 45 (9.0) 47 (9.3)
Mean (SD) white blood cell count (×10
9/l) 5.92 (1.76) 5.87 (1.61)
Mean (SD) haemoglobin (g/l) 118 (16) 118 (16)
Mean (SD) haematocrit (%) 36.5 (4.6) 36.6 (4.8)
Mean (SD) total protein (g/l) 66.8 (6.1) 67.2 (5.4)
Mean (SD) albumin (g/l) 37.3 (4.1) 37.6 (4.0)
Mean (SD) IgG (g/l) 15.88 (3.96) 16.24 (3.90)
Mean (SD) total cholesterol (mmol/l) 4.75 (1.03) 4.78 (1.03)
Mean (SD) cholinesterase (IU/l) 824.5 (163.3) 853.8 (190.9)
Mean (SD) creatine kinase (U/l) 69.0 (44.0) 72.6 (60.2)
Mean (SD) blood urea nitrogen (g/l) 6.78 (3.28) 6.60 (2.78)
Mean (SD) creatinine (μmol/l) 68.1 (37.1) 67.2 (30.1)
Mean (SD) sodium (mmol/l) 140.2 (3.9) 140.6 (3.74)
Mean (SD) potassium (mmol/l) 4.05 (0.56) 4.07 (0.60)
Mean (SD) chloride (mmol/l) 102.4 (4.4) 102.7 (4.3)
ECOG=Eastern Cooperative Oncology Group.
*From grade 0, fully active, able to carry on all pre-disease performance without restriction to grade 5, death.
†<15 g/day.
‡Includes patients with emphysema, bronchiectasis, and old pulmonary tuberculosis.
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and analysed using StatView software. In univariate
analysis we used the χ
2 test or Fisher’s exact test for
categoricaldataandtheMann-WhitneyUtestforcon-
tinuous variables. Logistic regression was used to esti-
mate the effectiveness of the vaccine in preventing
pneumococcal pneumonia, non-pneumococcal pneu-
monia, and all cause pneumonia. We used Kaplan-
Meier methods to calculate the survival curves. The
log rank test was used for time to event analyses and
Cox regression to calculate hazard ratios. P values are
two tailed. We considered a P value of <0.05 to be sta-
tistically different.
RESULTS
Overall, 428 of 1434 (29.8%) eligible participants
reviewed in the 23 nursing homes were excluded
(fig 1). Of the remaining 1006 participants, 502 were
randomised to the 23-valent pneumococcal poly-
saccharide vaccine and 504 to placebo. Table 1
shows the baseline characteristics of the two groups.
The exposure time was 1140 person years (mean 2.27
person years) in the vaccine group and 1149 (2.28) in
the placebo group (fig 1).
During follow-up, one episode of pneumonia was
diagnosed in 167 of the 1006 participants (16.6%),
with 141 requiring admission to hospital (52 from the
vaccine group, 89 from the placebo group). Although
someoftheparticipantshadmultipleepisodesofpneu-
monia (18 had two and three had three), only the first
episode was counted for statistical analysis. The inci-
dence of pneumonia did not differ significantly
among the 23 nursing homes, and none reported an
outbreak of pneumonia.
Results were obtained from blood culture for 122
participants, sputum culture for 134, and urinary anti-
gentestfor152.Allcausepneumoniawasdiagnosedin
12.5%(63/502)ofparticipantsinthevaccinegroupand
20.6% (104/504) in the placebo group. Pneumococcal
pneumonia was diagnosed in 51 participants (49 at the
first episode and two at recurrences); of these, 49 cases
were diagnosed by urinary antigen test, 41 were addi-
tionally diagnosed by sputum culture, and three by
blood culture. In 97 of the 167 participants with pneu-
moniaa full set oftests (sputum and bloodculturesand
urinary antigen test) was carried out. Causative patho-
genswereidentifiedin84(50%)ofthe167participants.
Thecausativeagentsofsomenon-pneumococcalpneu-
monia were Staphylococcus aureus (10/116, 9%),
Enterobacteriaceae (8/116, 7%), Haemophilus influenzae
(5/116, 4%), and Pseudomonas aeruginosa (3/116, 3%).
Pneumococcalpneumoniaandallcausepneumonia
were significantly more frequent in the placebo group
than in the vaccine group during follow-up. Pneumo-
coccal pneumonia was diagnosed in 2.8% (14/502) of
participants in the vaccine group and 7.3% (37/504) in
the placebo group. Invasive pneumococcal pneumo-
nia (positive result on blood culture) was diagnosed in
0%ofparticipantsinthevaccinegroupand0.6%(n=3)
in the placebo group. Non-pneumococcal pneumonia
was diagnosed in 9.8% (n=49) participants in the vac-
cine group and 13.3% (n=67) in the placebo group.
In the vaccine group the incidence of pneumococcal
pneumonia per 1000 person years was reduced by
63.8%andallcausepneumoniaby44.8%(table 2).Sur-
vival curves in the vaccine group compared with the
placebo group showed a significantly increased cumu-
lativeproportionofparticipantswithoutpneumococcal
pneumonia (fig 2) and all cause pneumonia (fig 3).
Significantly more participants with pneumococcal
pneumonia died in the placebo group than in the vac-
cine group: 35.1% (13/37) v 0% (0/14) (table 3). The
death rate for all cause pneumonia and non-pneumo-
coccal pneumonia was the same in both groups
(table 3). Among participants with all cause pneumo-
nia,20.6%(13/63)diedinthevaccinegroupcompared
with25.0%(26/104)intheplacebogroup.Amongpar-
ticipants with non-pneumococcal pneumonia, 26.5%
(13/49) died in the vaccine group compared with
19.4% (13/67) in the placebo group (table 3).
Overall, 89 participants in the vaccine group and 80
in the placebo group died from all causes—for exam-
ple, pneumonia, cerebrovascular disease, ischaemic
cardiomyopathy, renal failure, senility, and others.
Deaths from all causes did not differ between the
groups (fig 4).
DISCUSSION
The 23-valent pneumococcal polysaccharide vaccine
significantly prevented pneumococcal pneumonia
and reduced the death rate from pneumococcal pneu-
monia in nursing home residents.
To the best of our knowledge, this is the first rando-
mised controlled trial to show the efficacy of the 23-
Time (days)
C
u
m
u
l
a
t
i
v
e
 
p
r
o
p
o
r
t
i
o
n
 
o
f
 
 
p
a
r
t
i
c
i
p
a
n
t
s
w
i
t
h
o
u
t
 
p
n
e
u
m
o
c
o
c
c
a
l
 
p
n
e
u
m
o
n
i
a
 
0 200 400 600 800 1000 1200
0
0.80
0.85
0.90
0.95
1.00
Vaccine (n=399)
Hazard ratio 0.368 (95% CI 0.199 to 0.680)
P=0.0009
Placebo (n=387)
Fig 2 | Kaplan-Meier survival curves of participants without
pneumococcal pneumonia in vaccine and placebo groups
Table 2 |Incidence and reduction of primary end points in Japanese nursing home residents
assigned to 23-valent pneumococcal polysaccharide vaccine or placebo
End point
Incidence
(per 1000 person years)
% reduction in
incidence (95% CI) P value
Vaccine group
(n=502)
Placebo group
(n=504)
Pneumococcal pneumonia 12 32 63.8 (32.1 to 80.7) 0.0015
Non-pneumococcal pneumonia 43 59 29.4 (−4.3 to 52.3) 0.0805
All cause pneumonia 55 91 44.8 (22.4 to 60.8) 0.0006
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vaccine would be effective only against pneumococcal
pneumonia and not all cause pneumonia. However,
even though all cause pneumonia and pneumococcal
pneumonia were significantly more common in the
placebo group than vaccine group, the death rates
from all cause pneumonia and non-pneumococcal
pneumonia and the incidence of non-pneumococcal
pneumonia were not significantly reduced in the vac-
cine group.
Comparison with other studies
In the present study pneumonia occurred in 72.8 cases
per 1000 person years (167 cases/1006 people/2.28
years).Theclosefollow-upofthepopulationbythenur-
sing staff of the homes, the frequent rounds by the doc-
tors, and periodic visits by the study coordinator may
explain the apparently high incidence of pneumonia in
our study; however, the incidence is within the rate (33
to 114 cases per 1000 population per year) previously
reported in nursing home residents.
1 One study
reported functional disability or malnutrition as main
risk factors for pneumonia.
19 Consistent with this, our
participants exhibited a poor performance status (Eur-
opean Cooperative Oncology Group), malnutrition,
and a high incidence of chronic underlying diseases.
Evidence for the efficacy of the 23-valent pneumo-
coccal vaccine has been mainly obtained from studies
on patients with community acquired pneumonia.
20 A
large cohort study of patients with community
acquired pneumonia reported a 29% reduction in the
incidence of all cause pneumonia, a 44% reduction in
the incidence of invasive pneumococcal infection, and
a 35% reduction in the death rate from all cause pneu-
monia in the vaccine group.
21 In another large cohort
study, patients with community acquired pneumonia
who had been vaccinated with 23-valent pneumococ-
cal polysaccharide vaccine displayed about a 40%
lower rate of mortality or admission to an intensive
care unit compared with unvaccinated patients.
19 In
addition, previous randomised controlled trials in ger-
iatric institutions using lower valency pneumococcal
polysaccharide vaccine also support the efficacy of
the 23-valent pneumococcal vaccine found in the pre-
sent study.
1718 Significant reductions in the incidence
of pneumococcal pneumonia or all cause pneumonia
were reported in geriatric institutions using vaccine
containing only 2, 3, or 14 serotypes of pneumococcal
polysaccharides.
1718
Recent under-poweredrandomisedcontrolled trials
wereunabletoshowtheefficacyofthe23-valentpneu-
mococcal polysaccharide vaccine.
21 One trial investi-
gated the efficacy of the vaccine in 691 middle aged
and elderly people (50-85 years) based on the criteria
of a predicted high frequency of pneumococcal
pneumonia.
22 In this study, the vaccine was not found
to be efficacious against pneumonia or pneumococcal
pneumonia
22; however, this study had a smaller num-
ber of patients with pneumococcal pneumonia than
estimated.Inaddition, thediagnosticcriteriaforpneu-
mococcal pneumonia were not ideal; in 60% of parti-
cipants the diagnosis was based purely on an increase
in the concentrations of antibodies to pneumolysin in
pairedserumsamples.Anotherstudyshowedtheinac-
curacyofthepneumolysinmethodandthenecessityof
usingmorespecificcriteriafordiagnosingpneumococ-
cal pneumonia.
23 One randomised controlled trial in
HIV infected adults failed to show the efficacy of the
23-valent pneumococcal polysaccharide vaccine for
pneumonia or any invasive pneumococcal disease.
24
Inefficacy of the vaccine in this group of patients
could be attributed to the impaired production of cap-
sulespecificIgGduringthecourseofHIVinfection,as
it is well known that IgG cannot be elevated signifi-
cantly in this group of patients.
24
Strengths and limitations of the study
Theparticipantsinthisstudywereathighriskofpneu-
mococcal pneumonia. A sensitive and specific urinary
antigen test was used to determine the efficacy of the
vaccine. Intervention in patients with a high preva-
lence (22.2 per 1000 person years) of pneumococcal
pneumoniaandtheuseofa sensitiveandspecificdiag-
nostic method were important factors in showing the
efficacy of the vaccine.
The use of specimens from non-sterile sites may
affect the accuracy of a test for identifying causative
organisms; thus, even though we used strict criteria
for determining the causes, one of the limitations of
the current study was the use of sputum and urine to
diagnose pneumococcal pneumonia. Future studies
need to confirm the efficacy of the 23-valent pneumo-
coccal vaccine using only specimens from sterile sites.
Another limitation of this study was that antibody
Table 3 |Death rates among nursing home residents randomised to 23-valent pneumococcal
polysaccharide vaccine or to placebo (sodium chloride). Values are numbers (percentages)
unless stated otherwise
Diagnosis
Death rates
Vaccine group
(n=502)
Placebo group
(n=504) P value
Pneumococcal pneumonia 0/14 (0) 13/37 (35.1) 0.0105
Non-pneumococcal pneumonia 13/49 (26.5) 13/67 (19.4) 0.3632
All cause pneumonia 13/63 (20.6) 26/104 (25.0) 0.5181
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Fig 3 | Kaplan-Meier survival curves of participants without all
cause pneumonia in vaccine and placebo groups
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related with clinical outcomes.
Conclusions and policy implications
Because of a steadily increasing elderly population in
developed countries, nursing homes are often over-
crowded. The incidence of infectious diseases such as
pneumococcal pneumonia is common in elderly peo-
ple because of their impaired host defence mechan-
isms. The rate of sporadic pneumococcal diseases
among nursing home residents is almost 14 times as
high as that among elderly people living in the
community.
25 In all of the reported nursing home out-
breaks, less than 5% of the residents had reportedly
been vaccinated.
5-7 The efficacy of the 23-valent pneu-
mococcalvaccinewasreportedagainstoneoutbreakof
multidrug resistant pneumococcal infection in nursing
homes in Oklahoma.
5 No additional cases of pneumo-
nia occurred and the rates of carriage decreased sub-
stantially after residents received the vaccine.
5 Our
findings, together with these previous reports, suggest
the importance of vaccinating residents of nursing
homes. Because of the increase in the elderly popula-
tion, a progressive increase in the incidence of pneu-
monia can also be predicted in elderly people living in
the community; future investigations should focus on
the efficacy of the 23-valent pneumococcal vaccine in
this population.
The Ministry of Health, Labour and Welfare of
Japanhavenotproducedanyofficialrecommendation
to immunise nursing home residents using 23-valent
pneumococcal polysaccharide vaccine. The main rea-
sonforthisisthelackofarandomisedandprospective
study on the efficacy of the vaccine. The results of the
present trial show the preventive effect of the vaccine
on pneumococcal pneumonia in nursing home resi-
dents in Japan. This finding suggests the need for a
national policy that recommends the systematic vacci-
nation of residents living in institutions to reduce mor-
bidity as well as the cost of health care in Japan.
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placebo groups
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